A year has passed since the Ministry of Health, Labor and Welfare (MHLW) announced its package strategy to fuel the early commercialization of software as a medical device (SaMD) in November last year. A growing number of drug makers are…
REGULATORY
Health Minister Stresses Basic 8-Month Interval for Booster Shot
The interval between the second doses of COVID-19 vaccines and booster shots is “eight months in principle,” Health Minister Shigeyuki Goto stressed on November 16 after experts’ decision to allow the possible shortening of this period caused confusion among municipal…
To read the full story
Related Article
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- COVID-19 Expert Omi Urges Govt to Consider Booster Shots
September 9, 2021
REGULATORY
- 227 Billion Yen for Dual Use Manufacturing Facilities: FY2021 METI Extra Budget
November 29, 2021
- MHLW Earmarks 608 Billion Yen for COVID-19 Drug Initiatives: FY2021 Extra Budget
November 29, 2021
- Idorsia’s Cerebral Vasospasm Drug, Efient Label Expansion Clear PAFSC
November 29, 2021
- PMDA Reviewing Safety Risk of Imusera/Gilenya
November 29, 2021
- Olumiant Gets Sakigake Tag for Type I IFN Autoinflammatory Diseases
November 29, 2021
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…